Are Measurements of LDL Particles Ready for Prime Time?(Editorials) Are Measurements of LDL Particles Ready for Prime Time?(Editorials)

Are Measurements of LDL Particles Ready for Prime Time?(Editorials‪)‬

Clinical Chemistry, 2006, Sept, 52, 9

    • €2.99
    • €2.99

Publisher Description

In this issue of Clinical Chemistry, Ensign et al. (1) report on the differences in 4 methods commonly used to assess LDL subfractions or particles. The results are both interesting and deeply disturbing. In a careful, well-planned study, Ensign and colleagues prospectively and simultaneously collected blood samples as required for each method. Sample analyses by 3 of the methods in question, nuclear magnetic resonance (NNIR), density gradient ultra-centrifugation (VAP), and gradient gel electrophoresis (GGE), were performed by the laboratories that developed and commercially offer these technologies. The fourth technique, tube gel electrophoresis (TGE), is sold as a commercial reagent set and was performed in the investigators' own laboratory according to the manufacturer's specifications. The primary result investigated was LDL pattern, as interpreted by the reporting laboratories. Other results reported by some of the laboratories included particle number/concentration and LDL cholesterol (LDL-C), the current focus of national and international treatment guidelines and therapeutic goals (2, 3).

GENRE
Science & Nature
RELEASED
2006
1 September
LANGUAGE
EN
English
LENGTH
8
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
PROVIDER INFO
The Gale Group, Inc., a Delaware corporation and an affiliate of Cengage Learning, Inc.
SIZE
161.4
KB
Lack of Agreement of Homogeneous Assays with the Reference Method for Ldl-Cholesterol May Not Indicate Unreliable Prediction of Risk for Cardiovascular Disease (Letters) (Letter to the Editor) Lack of Agreement of Homogeneous Assays with the Reference Method for Ldl-Cholesterol May Not Indicate Unreliable Prediction of Risk for Cardiovascular Disease (Letters) (Letter to the Editor)
2002
Estimating LDL Apob: Infomania Or Clinical Advance?(Editorial) (Clinical Report) Estimating LDL Apob: Infomania Or Clinical Advance?(Editorial) (Clinical Report)
2008
Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders?(Lipids, Lipoproteins, And Cardiovascular Risk Factors) Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders?(Lipids, Lipoproteins, And Cardiovascular Risk Factors)
2002
High-Density Lipoproteins High-Density Lipoproteins
2011
Molecular Epidemiology of Chronic Diseases Molecular Epidemiology of Chronic Diseases
2011
Plasma Paraoxonase Activity in Patients with Systemic Sclerosis. Plasma Paraoxonase Activity in Patients with Systemic Sclerosis.
2009
Impact of the Third Cholesterol Report from the Adult Treatment Panel of the National Cholesterol Education Program on the Clinical Laboratory (Special Report) Impact of the Third Cholesterol Report from the Adult Treatment Panel of the National Cholesterol Education Program on the Clinical Laboratory (Special Report)
2002
DNA Methylation Changes in Sera of Women in Early Pregnancy are Similar to Those in Advanced Breast Cancer Patients (Technical Briefs) DNA Methylation Changes in Sera of Women in Early Pregnancy are Similar to Those in Advanced Breast Cancer Patients (Technical Briefs)
2004
Colorectal Carcinoma Susceptibility and Metastases are Associated with Matrix Metalloproteinase-7 Promoter Polymorphisms (Technical Briefs) Colorectal Carcinoma Susceptibility and Metastases are Associated with Matrix Metalloproteinase-7 Promoter Polymorphisms (Technical Briefs)
2003
High-Sensitivity C-Reactive Protein As a Predictor of All-Cause Mortality: Implications for Research and Patient Care (Editorial) High-Sensitivity C-Reactive Protein As a Predictor of All-Cause Mortality: Implications for Research and Patient Care (Editorial)
2008
Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer (Technical Briefs) Biological Variation of Tumor Markers and Its Application in the Detection of Disease Progression in Patients with Non-Small Cell Lung Cancer (Technical Briefs)
2005
Hemoglobin Variants and Hemoglobin [a.Sub.1C] Analysis: Problem Solved?(Editorial) Hemoglobin Variants and Hemoglobin [a.Sub.1C] Analysis: Problem Solved?(Editorial)
2003